Bunkerhill Raises $55m For Carebricks Agentic AI Platform
AI News reported that Bunkerhill Health raised $55 million to scale Carebricks, its agentic AI platform for health systems. The report names Cleveland Clinic, UTMB and Intermountain Health as current users, while pricing, contract values and broader clinical outcome data remain undisclosed.
Bunkerhill Health raised $55 million to scale Carebricks, an agentic AI platform already running at Cleveland Clinic, the University of Texas Medical Branch and Intermountain Health.
The Series B included Sequoia Capital, Felicis, Optum Ventures, Y Combinator and Khosla Ventures.
The named deployments give the financing an operating record beyond research-stage claims.
Hospitals Build Their Own Carebricks Agents
Carebricks lets hospitals build agents for different workflows instead of buying one fixed product.
Some review cardiology images for early signs of heart disease and flag patients for follow-up care; others handle prior authorisations or keep registry data current.
Bunkerhill chief executive Nishith Khandwala said medicine has advanced faster than the healthcare system's ability to operationalise it.
He positioned agents as a way for health systems to turn more improvement ideas into practice when workforce capacity is limited.
Centers for Medicare & Medicaid Services put US healthcare spending at $5.3 trillion in 2024, while labour shortages continue to strain providers.
UTMB Runs More Than 20 Agents
UTMB chief AI officer Dr Peter McCaffrey said the health system has more than 20 agents live across clinical care, operations and administration.
During its first month, a coronary-calcium agent flagged a patient using an FDA-cleared algorithm.
Cardiology confirmed the heart-attack risk and clinicians performed a triple bypass; UTMB's care team credited the early detection with saving the patient's life.
UTMB also reported that a nephrology triage agent prioritises patients by severity, routes others to telemedicine and cut average specialist wait times by more than 50 percent.
For lung-nodule follow-up, another agent tracks incidental CT findings through the required next step.
UTMB recorded an 80 percent faster response on urgent cases, twice the rate of guideline-concordant follow-up and less manual coordinator work.
Those results remain tied to UTMB.
No peer-reviewed study, patient cohort size, false-positive rate or comparative outcome data accompanied the deployment account.
Funding Supports A Wider Rollout
Khosla Ventures founder Vinod Khosla identified health-system adoption, rather than the technology alone, as the main bottleneck for healthcare AI.
He pointed to Bunkerhill's traction in large health systems.
The new capital can support sales and deployment, but the named examples do not establish measured clinical performance across every Carebricks site.
Independent outcome data for the wider customer base has not been published.
